A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia.
AffiliationMaternal and Fetal Health Research Group, St Mary's Hospital, University of Manchester, Manchester, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractOBJECTIVE: Progress in the prevention and treatment of women at risk of pre-eclampsia (PE) still remains hindered by the lack of clinical screening tools that can accurately predict which mothers are at risk. The identification and validation of predictive biomarkers is therefore seen as a critical milestone towards improved healthcare provision and the clinical testing of new therapeutic strategies. Gel-free proteomic technologies offer the capability of analysing hundreds of plasma proteins simultaneously, but as yet these methods have not been applied to pregnancy complications. To assess the feasibility of such an approach to plasma biomarker research in pregnancy we have applied the technique to samples from women with PE to gestation-matched controls. SAMPLE: Pooled plasma samples taken at time of disease from women with PE (n = 23) and gestation-matched controls (n = 23). METHODS: Proteomics strategy for relative quantification of proteins using mass spectrometry. RESULTS: We identified several differences, including elevated levels of endoglin, PAPP-A and PSG1 in PE plasma. Increased levels of endoglin were validated using immunoassay analysis of individual plasma samples. CONCLUSIONS: Although at a relatively early stage, this mass spectrometry-based approach shows promise as a tool to identify global protein changes in plasma. The application of these methods to pre-disease samples is the next step in the identification of clinically useful biomarkers.
CitationA proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia. 2009, 116 (11):1473-80 BJOG
- A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease.
- Authors: Blumenstein M, McMaster MT, Black MA, Wu S, Prakash R, Cooney J, McCowan LM, Cooper GJ, North RA
- Issue date: 2009 Jun
- Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia.
- Authors: Rasanen J, Girsen A, Lu X, Lapidus JA, Standley M, Reddy A, Dasari S, Thomas A, Jacob T, Pouta A, Surcel HM, Tolosa JE, Gravett MG, Nagalla SR
- Issue date: 2010 Aug 6
- Identification of proteomic biomarkers of preeclampsia in amniotic fluid using SELDI-TOF mass spectrometry.
- Authors: Park JS, Oh KJ, Norwitz ER, Han JS, Choi HJ, Seong HS, Kang YD, Park CW, Kim BJ, Jun JK, Syn HC
- Issue date: 2008 May
- Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers.
- Authors: Nagalla SR, Canick JA, Jacob T, Schneider KA, Reddy AP, Thomas A, Dasari S, Lu X, Lapidus JA, Lambert-Messerlian GM, Gravett MG, Roberts CT Jr, Luthy D, Malone FD, D'Alton ME
- Issue date: 2007 Apr
- Complement component C4A and apolipoprotein A-I in plasmas as biomarkers of the severe, early-onset preeclampsia.
- Authors: Zhang H, Zhang Y, Yang F, Li L, Liu S, Xu Z, Wang J, Sun S
- Issue date: 2011 Aug